Comparative analysis of the manufacturing carbon footprint of biologics for severe asthma.

ABSTRACT:

Objective

To quantify, compare and analyse the carbon emissions of biologic treatments for severe asthma.

Design

Cradle-to-gate carbon emissions (from raw materials to finished product) for six monoclonal antibody therapies, benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab and tezepelumab, were estimated using Medicine Carbon Footprint Classifier, a standardised, mass-based method for medicine carbon footprinting. A representative patient, eligible for all therapies, was defined to enable comparisons. Sensitivity, scenario and pairwise analyses were conducted to explore variations in emissions and opportunities for reduction.

Outcome measures

The primary outcome was first-year carbon emissions of biologic treatments for a representative patient with severe

SUBMITTER: Taylor H 

PROVIDER: S-EPMC12778224 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature